Education
About Us
Working with TipRanks
Follow Us
MiMedx Group Inc. (MDXG)
:MDXG
MDXG Stock Chart & Stats
$6.75
$0.12(1.36%)
At close: 4:00 PM EST
$6.75
$0.12(1.36%)
Day’s Range― - ―
52-Week Range$5.79 - $10.14
Previous CloseN/A
Volume99.42K
Average Volume (3M)830.42K
Market Cap
$1.14B
Enterprise Value$921.13M
Total Cash (Recent Filing)$142.08M
Total Debt (Recent Filing)$1.38M
Price to Earnings (P/E)28.2
Beta0.84
Next Earnings
Mar 04, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding148,102,160
10 Day Avg. Volume1,257,155
30 Day Avg. Volume830,421
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)7.32
Price to Sales (P/S)4.05
P/FCF Ratio21.92
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue2.34
Enterprise Value/Gross Profit2.86
Enterprise Value/Ebitda13.15
Forecast
1Y Price Target
$12.00Price Target Upside77.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PositionMDXG continues to grow versus difficult prior-year comparisons, a testament to the company's execution.
Product SalesMDXG put up another quarter of strong product sales, with $93mn of revenue versus $89.4mn Street, or 7% growth versus 3% expectation.
Strategic InitiativesManagement remains optimistic about current strategic initiatives, with the recent launch of HELIOGEN expected to contribute meaningfully.
Bears Say
Market ChallengesPotential $1.0-1.5bn in Medicare Skin Sub payments still up for grabs.
Reimbursement UncertaintyContinuing reimbursement uncertainty disrupted the business in the physician office setting.
MiMedx Group News
MDXG FAQ
What was MiMedx Group Inc.’s price range in the past 12 months?
MiMedx Group Inc. lowest stock price was $5.79 and its highest was $10.14 in the past 12 months.
What is MiMedx Group Inc.’s market cap?
MiMedx Group Inc.’s market cap is $1.14B.
When is MiMedx Group Inc.’s upcoming earnings report date?
MiMedx Group Inc.’s upcoming earnings report date is Mar 04, 2026 which is in 104 days.
How were MiMedx Group Inc.’s earnings last quarter?
MiMedx Group Inc. released its earnings results on Oct 29, 2025. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.077 by $0.033.
Is MiMedx Group Inc. overvalued?
According to Wall Street analysts MiMedx Group Inc.’s price is currently Undervalued.
Does MiMedx Group Inc. pay dividends?
MiMedx Group Inc. does not currently pay dividends.
What is MiMedx Group Inc.’s EPS estimate?
MiMedx Group Inc.’s EPS estimate is 0.09.
How many shares outstanding does MiMedx Group Inc. have?
MiMedx Group Inc. has 148,102,160 shares outstanding.
What happened to MiMedx Group Inc.’s price movement after its last earnings report?
MiMedx Group Inc. reported an EPS of $0.11 in its last earnings report, beating expectations of $0.077. Following the earnings report the stock price went up 2.921%.
Which hedge fund is a major shareholder of MiMedx Group Inc.?
Currently, no hedge funds are holding shares in MDXG
MiMedx Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (77.78% Upside)
$12.00 (77.78% Upside)
Blogger Sentiment
Bullish
MDXG Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 491.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.67%
12-Months-Change
Fundamentals
Return on Equity
19.44%
Trailing 12-Months
Asset Growth
30.79%
Trailing 12-Months
Company Description
MiMedx Group Inc.
MiMedx Group, Inc. (MDXG) is a biotechnology company specializing in regenerative medicine and wound care products derived from human placental tissue. The company focuses on developing and commercializing innovative solutions for the treatment of chronic and acute wounds, surgical wounds, and orthopedic conditions. MiMedx's core offerings include allograft tissue products, which are used to promote healing and tissue regeneration, primarily in the fields of orthopedics, wound care, and surgical applications.
MDXG Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance for the third quarter with record revenue and significant growth in major business areas. However, uncertainty around upcoming Medicare reimbursement reforms and ongoing legal expenses were highlighted as potential challenges. The company expressed confidence in its ability to navigate these uncertainties and continue its growth trajectory.View all MDXG earnings summariesMDXG Stock 12 Month Forecast
Average Price Target
$12.00
▲(77.78% Upside)
Technical Analysis
Oric Pharmaceuticals
―
Pharming Group
―
ATAI Life Sciences
―
Maze Therapeutics, Inc.
―
Ownership Overview
2.13% Insiders
9.70% Mutual Funds
37.57% Other Institutional Investors
40.48% Public Companies and
Individual Investors